KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Acquisitions & Divestments: 2021-2024

Historic Change in Acquisitions & Divestments for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2024 value amounting to $937.9 million.

  • AbCellera Biologics' Change in Acquisitions & Divestments fell 57.73% to $83.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $588.4 million, marking a year-over-year decrease of 41.39%. This contributed to the annual value of $937.9 million for FY2024, which is 2.96% up from last year.
  • As of FY2024, AbCellera Biologics' Change in Acquisitions & Divestments stood at $937.9 million, which was up 2.96% from $910.9 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Change in Acquisitions & Divestments ranged from a high of $937.9 million in FY2024 and a low of $27.6 million during FY2021.
  • Over the past 3 years, AbCellera Biologics' median Change in Acquisitions & Divestments value was $910.9 million (recorded in 2023), while the average stood at $786.5 million.
  • Data for AbCellera Biologics' Change in Acquisitions & Divestments shows a peak YoY surged of 1,749.58% (in 2022) over the last 5 years.
  • AbCellera Biologics' Change in Acquisitions & Divestments (Yearly) stood at $27.6 million in 2021, then surged by 1,749.58% to $510.6 million in 2022, then skyrocketed by 78.39% to $910.9 million in 2023, then grew by 2.96% to $937.9 million in 2024.